Results 21 to 30 of about 5,472 (197)

The effects of vasopressin and its analogues on the liver and its disorders in the critically ill: [PDF]

, 2010
Purpose of review: Vasopressin and terlipressin, a long-acting V1a analogue, are increasingly used in intensive care. The main clinical indications are the treatment of patients with septic shock and of patients with cirrhosis, who develop variceal ...
F. Oberti, P. Asfar, P. Calès, P. Radermacher   +3 more
core   +2 more sources

Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis [PDF]

, 2013
BACKGROUND: Terlipressin, as a prodrug of vasopressin, has agonistic effects on the V1 receptor and partial agonistic effects on renal vasopressin V2 receptors. However, its effects on serum sodium concentration are controversial.
Dae-Hong Jeon, Dong Park, Eun Bae, Ha Jang, Hyun Cho, Kyungo Hwang, Se-Ho Chang, Yeo-Jin Kang   +7 more
core   +1 more source

Protection of cerebral microcirculation, mitochondrial function and electrocortical activity by small-volume resuscitation with terlipressin in a model of haemorrhagic shock [PDF]

, 2017
Background During early treatment of haemorrhagic shock, cerebral perfusion pressure can be restored by small-volume resuscitation with vasopressors. Whether this therapy is improved with additional fluid remains unknown.
Chisholm, KI, Duchen, MR, Dyson, A, Ida, KK, Malbouisson, LMS, Papkovsky, DB, Singer, M, Smith, KJ   +7 more
core   +1 more source

Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1 [PDF]

, 2017
Background Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis.
Alessandria, Angeli, Arroyo, Belcher, Belcher, Besso, Boyer, Cavallin, Fernández, Gillies, Gluud, Hadengue, Mandal, Marik, Martin-Llahi, Martin-Llahi, Mattos, Moher, Navasa, Neri, Newby, Platt, Ruiz-del-Arbol, Salerno, Salerno, Salmeron, Sanyal, Schepke, Sharma, Silawat, Singh, Solanki, Srivastava, Tavakkoli, Wood   +34 more
core   +3 more sources

Vasopressin and Terlipressin in the Treatment of Vasodilatory Septic Shock: A Systematic Review

Proceedings of Singapore Healthcare, 2011
Background: Vasodilatory septic shock unresponsive to fluid resuscitation requires the addition of vasopressors. Catecholamines remain the first line vasopressor therapy, but treatment failure is a potential problem.
Jie Lin Soong BSc (Pharm) (Hons), Wai Hing Lim B Pharm (Hons), M Clin Pharm   +1 more
doaj   +1 more source

Terlipressin-induced hyponatremic encephalopathy in a noncirrhotic patient

Kaohsiung Journal of Medical Sciences, 2013
Terlipressin, an analogue of vasopressin, is frequently used for the management of esophageal varices bleeding and hepatorenal syndrome. Terlipressin therapy in portal hypertensive patients is frequently associated with hyponatremia, but is rarely ...
Yao-Kuang Wang, Daw-Yang Hwang, Sophie S.W. Wang, Shang-Jyh Hwang, Li-Tzong Chen, Mei-Chuan Kuo   +5 more
doaj   +1 more source

Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico

Annals of Hepatology, 2009
Introduction. Type 1 hepatorenal syndrome (HRS) is a functional renal failure that complicates end-stage cirrhosis. The vasopressin analogue terlipressin has been associated with improved renal function in patients with type 1 HRS.Aim.
Linda E. Muñoz, Eliud G. Alcalá, Paula Cordero, Manuel A. Martinez, Nathalie Y. Vázquez, Susana Galindo, Eduardo Mendoza, José J. Segura   +7 more
doaj   +1 more source

Practice guidance for the use of terlipressin for liver cirrhosis–related complications

Therapeutic Advances in Gastroenterology, 2022
Background: Liver cirrhosis is a major global health burden worldwide due to its high risk of morbidity and mortality. Role of terlipressin for the management of liver cirrhosis–related complications has been recognized during recent years.
Xingshun Qi, Zhaohui Bai, Qiang Zhu, Gang Cheng, Yu Chen, Xiaowei Dang, Huiguo Ding, Juqiang Han, Lei Han, Yingli He, Fanpu Ji, Hongxu Jin, Bimin Li, Hongyu Li, Yiling Li, Zhiwei Li, Bang Liu, Fuquan Liu, Lei Liu, Su Lin, Dapeng Ma, Fanping Meng, Ruizhao Qi, Tianshu Ren, Lichun Shao, Shanhong Tang, Yufu Tang, Yue Teng, Chunhui Wang, Ran Wang, Yunhai Wu, Xiangbo Xu, Ling Yang, Jinqiu Yuan, Shanshan Yuan, Yida Yang, Qingchun Zhao, Wei Zhang, Yongping Yang, Xiaozhong Guo, Weifen Xie   +40 more
doaj   +1 more source

INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion

Contemporary Clinical Trials Communications, 2023
Background: Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of
Ethan Weinberg, Suditi Rahematpura, Stevan A. Gonzalez, Manhal J. Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Jade Ikahihifo-Bender, Maggie Harte, Grace Kim-Lee, Sherry Witkiewicz, William Tobin, Khurram Jamil, Zachary Fricker, K. Rajender Reddy   +14 more
doaj   +1 more source

The haemodynamic effects of the perioperative terlipressin infusion in living donor liver transplantation: A randomised controlled study

Indian Journal of Anaesthesia, 2015
Background and Aims: Liver disease is usually accompanied with a decline in systemic vascular resistance (SVR). We decided to assess effects of the peri-operative terlipressin infusion on liver donor liver transplantation recipients with respect to ...
Nagwa Ibrahim, Ashraf Hasanin, Sabry Abd Allah, Eman Sayed, Mohamed Afifi, Khaled Yassen, Wesam Saber, Magdy Khalil   +7 more
doaj   +1 more source